Oxolife, member of CATALONIA.HEALTH, has successfully presented the promising results of its Phase 2 study of its new OXO-001 research drug at the 40th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), held in Amsterdam.  

The presentation of the results received the special award for Best Scientific Communication from ESHRE in collaboration with the Fertility Society of Australia and New Zealand. This award highlights the company's commitment to innovation and its positive impact on the field of fertility. 

The results of the Phase 2 study will soon be published in the prestigious journal Human Reproduction. In addition, with the promising results of the second phase, Oxolife will carry out a confirmatory Phase 3 study in the European Union, which will include women using their own eggs. 

In addition, Oxolife is currently raising funds looking for potential partners and funding opportunities to accelerate the development and commercialization process of this innovative treatment. 

Related news: 

• OXOART2, clinical study of Oxolife, selected as one of the most outstanding presented at the 40th annual meeting of ESHRE (10 July 2024)